Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 52

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 52
---
 collaborators; 

•our contractual or other obligations to provide resources to fund our products and services and to provide resources to our collaborations; 

•delays or failures in advancement of future products in clinical trials by us or our collaborators; 

•risks associated with any future international expansion of our business, including the potential to conduct clinical trials and commercialize our products and services in multiple international locations; 

•our ability and that of our collaborators to consistently manufacture our products; 

•our dependence on, and the need to attract and retain, key management and other personnel; 

•our ability to obtain, protect and enforce our intellectual property rights; 

•our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies; 

•our ability to obtain additional capital that may be necessary to expand our business; 

•our ability to accurately report our financial results in a timely manner; 

•business interruptions such as power outages, strikes, acts of terrorism or natural disasters; and 

29

•our ability to use our net operating loss (“NOL”) carryforwards to offset future taxable income. 

The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. 

While as a general matter we intend to periodically report on the status of our development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure of any such milestones related to any of our products that are managed by our collaborators. Any disclosure by us or our collaborators of data that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our products, including adverse safety events reported for any of our products.

If third-party payors, including private payors and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our clinical diagnostic products, our commercial success will be negatively affected. 

Our diagnostic revenue depends in part on achieving broad coverage and reimbursement for our clonoSEQ tests from payors, including both private and government payors.